Latest News
Jan 9, 2018

On Jan. 9, 2018, Mylan N.V. completed the $1 billion share repurchase plan that was previously approved by the Board of Directors of Mylan N.V.

Jan 8, 2018

Global pharmaceutical leader Mylan N.V. (NASDAQ, TASE: MYL) today announced that it is completing its previously-approved $1 billion share repurchase plan. Mylan's Chairman Robert J. Coury...

Jan 3, 2018

Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) and Mylan N.V. (NASDAQ, TASE: MYL) today announced the development strategy for M710, a proposed biosimilar to EYLEA® (aflibercept) injection. EYLEA...

Dec 29, 2017

Global pharmaceutical leader Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Estradiol Vaginal Cream USP, 0.01%, the first generic version of Allergan's Estrace® Cream. Mylan...

Dec 29, 2017

Biosimilar Trastuzumab, co-developed by Biocon Ltd. (BSE code: 532523, NSE: BIOCON) and Mylan N.V. (NASDAQ, TASE: MYL), has been approved by ANVISA, the Brazilian regulatory agency, through their...

View More


Search News Releases

Contact Mylan Communications

Global Communications 
724.514.1968
communications@mylan.com

Stay Connected